SPO11: A Potential Drug Target and Biomarker (G23626)

Target Name: SPO11

NCBI ID: G23626

SPO11

SPO11: A Potential Drug Target and Biomarker

SPO11 is a protein that is covalently bound to DNA damage-inducible switch (DSB-like) proteins. It is a small non-coding RNA molecule that plays a crucial role in the regulation of gene expression and DNA replication. SPO11 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SPO11 functions as a negative regulator of the Runx1 gene, which is a critical regulator of hematopoietic stem cell proliferation and differentiation. Runx1 is a transcription factor that has been implicated in the development and maintenance of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SPO11 functions as a negative regulator of Runx1 by binding to its DNA and preventing it from binding to the RNA polymerase II, which is necessary for gene expression.

SPO11 has also been shown to play a role in the regulation of DNA replication and repair. the regulation of cell cycle progression, by preventing the progression of cells into the G1 phase and by regulating the entry of cells into the S phase.

SPO11 has been implicated in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that SPO11 is overexpressed in many cancer tissues and that it is involved in the regulation of cell proliferation and apoptosis. Similarly, SPO11 has been shown to be overexpressed in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and to be involved in the regulation of neurotransmitter synthesis and release.

SPO11 has also been shown to be involved in the regulation of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that SPO11 is overexpressed in rheumatoid arthritis tissues and that it is involved in the regulation of immune cell function and the production of autoantibodies. Similarly, SPO11 has been shown to be involved in the regulation of multiple sclerosis, by preventing the development of CD4+ T cells in the central nervous system.

SPO11 has been shown to be involved in a variety of cellular processes, including cell growth, cell cycle progression, and DNA replication. It has been shown to interact with a variety of cellular components, including the DNA replication machinery, the cell cycle kinase cyclin D1, and the transcription factor Runx1.

SPO11 has also been shown to have potential therapeutic applications. For example, studies have shown that SPO11 can be used as a drug target to inhibit the activity of Runx1 and to prevent the development of cancer. Methods such as RNA interference and protein inhibition have been shown to be effective in reducing the expression of SPO11 and in inhibiting the activity of Runx1.

In addition to its potential therapeutic applications, SPO11 is also a potential biomarker for a variety of diseases. For example, studies have shown that SPO11 can be used as a biomarker for cancer, by measuring its expression in tumor tissue and patient samples. Similarly, SPO11 has been shown to be involved in the regulation of DNA replication and repair, which could be used as a biomarker for the assessment of DNA damage in cancer cells.

Overall, SPO11 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand its functions and to develop effective therapies based on it.

Protein Name: SPO11 Initiator Of Meiotic Double Stranded Breaks

Functions: Component of a topoisomerase 6 complex specifically required for meiotic recombination. Together with TOP6BL, mediates DNA cleavage that forms the double-strand breaks (DSB) that initiate meiotic recombination. The complex promotes relaxation of negative and positive supercoiled DNA and DNA decatenation through cleavage and ligation cycles. Essential for the phosphorylation of SMC3, HORMAD1 and HORMAD2

The "SPO11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPO11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets